Background Information Metastatic castration-resistant prostate cancer (mCRPC) is a form of prostate cancer that keeps growing even when male hormones like testosterone are decreased to very low levels. Current treatments include drugs that block these hormones, chemotherapy, and hormone therapies. However, these treatments can stop working overtime. This clinical trial aims to test the safety and effectiveness of an investigational drug called MK-5684 to see if it may help stop or slow the spread of prostate cancer, specifically mCRPC. The study will look at how well MK-5684 may work...

This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and whose cancer progressed on or after they were previously treated with next-generation Hormonal Agent (NHA).  Study of Investigational Drug, MK5684, in Participants with Metastatic Castration-Resistant Prostate Cancer  Patient Summary  This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and whose cancer progressed on or after they were previously treated with a next-generation Hormonal Agent (NHA).  This trial is comparing the...

This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.  Study of Investigational Drug, MK5684, in Participants with Metastatic Castration-Resistant Prostate Cancer Patient Summary The Omaha-003 clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and failed to respond to drugs or surgery to block the testes from making hormones and after treatment with...